Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’
Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, Véronique Dièras, Hiroaki Iwata, Sherene Loi, Hope S. Rugo, Andreas Schneeweiß, Eric P. Winer, S. Patel, Volkmar Henschel, A. Swat, Manika Kaul, Luciana Molinero, S. Patel, Jane Yuet Ching Hui, Peter Schmid
Abstract
The authors regret that in the original publication the figure presented in Supplementary Material as Fig. S3 contained a labelling error. In the original figure should “ITT” read “PD-L1 IC+”. The figure has now been corrected and replaced online. The authors would like to apologise for any inconvenience caused. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysisAnnals of OncologyVol. 32Issue 8PreviewGuidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. Full-Text PDF Open Access